-
Je něco špatně v tomto záznamu ?
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial
N. Tofte, M. Lindhardt, K. Adamova, SJL. Bakker, J. Beige, JWJ. Beulens, AL. Birkenfeld, G. Currie, C. Delles, I. Dimos, L. Francová, M. Frimodt-Møller, P. Girman, R. Göke, T. Havrdova, HJL. Heerspink, A. Kooy, GD. Laverman, H. Mischak, G. Navis,...
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, pozorovací studie, randomizované kontrolované studie, práce podpořená grantem
- MeSH
- albuminurie MeSH
- antagonisté mineralokortikoidních receptorů terapeutické užití MeSH
- časná diagnóza MeSH
- diabetes mellitus 2. typu farmakoterapie patofyziologie moč MeSH
- diabetické nefropatie farmakoterapie patofyziologie moč MeSH
- dospělí MeSH
- hodnoty glomerulární filtrace MeSH
- lidé středního věku MeSH
- lidé MeSH
- progrese nemoci MeSH
- prospektivní studie MeSH
- proteomika MeSH
- senioři MeSH
- spironolakton terapeutické užití MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: Microalbuminuria is an early sign of kidney disease in people with diabetes and indicates increased risk of cardiovascular disease. We tested whether a urinary proteomic risk classifier (CKD273) score was associated with development of microalbuminuria and whether progression to microalbuminuria could be prevented with the mineralocorticoid receptor antagonist spironolactone. METHODS: In this multicentre, prospective, observational study with embedded randomised controlled trial (PRIORITY), we recruited people with type 2 diabetes, normal urinary albumin excretion, and preserved renal function from 15 specialist centres in ten European countries. All participants (observational cohort) were tested with the CKD273 classifier and classified as high risk (CKD273 classifier score >0·154) or low risk (≤0·154). Participants who were classified as high risk were entered into a randomised controlled trial and randomly assigned (1:1), by use of an interactive web-response system, to receive spironolactone 25 mg once daily or matched placebo (trial cohort). The primary endpoint was development of confirmed microalbuminuria in all individuals with available data (observational cohort). Secondary endpoints included reduction in incidence of microalbuminuria with spironolactone (trial cohort, intention-to-treat population) and association between CKD273 risk score and measures of impaired renal function based on estimated glomerular filtration rate (eGFR; observational cohort). Adverse events (particularly gynaecomastia and hyperkalaemia) and serious adverse events were recorded for the intention-to-treat population (trial cohort). This study is registered with the EU Clinical Trials Register (EudraCT 20120-004523-4) and ClinicalTrials.gov (NCT02040441) and is completed. FINDINGS: Between March 25, 2014, and Sept 30, 2018, we enrolled and followed-up 1775 participants (observational cohort), 1559 (88%) of 1775 participants had a low-risk urinary proteomic pattern and 216 (12%) had a high-risk pattern, of whom 209 were included in the trial cohort and assigned to spironolactone (n=102) or placebo (n=107). The overall median follow-up time was 2·51 years (IQR 2·0-3·0). Progression to microalbuminuria was seen in 61 (28%) of 216 high-risk participants and 139 (9%) of 1559 low-risk participants (hazard ratio [HR] 2·48, 95% CI 1·80-3·42; p<0·0001, after adjustment for baseline variables of age, sex, HbA1c, systolic blood pressure, retinopathy, urine albumin-to-creatinine ratio [UACR], and eGFR). Development of impaired renal function (eGFR <60 mL/min per 1·73 m2) was seen in 48 (26%) of 184 high-risk participants and 119 (8%) of 1423 low-risk participants (HR 3·50; 95% CI 2·50-4·90, after adjustment for baseline variables). A 30% decrease in eGFR from baseline (post-hoc endpoint) was seen in 42 (19%) of 216 high-risk participants and 62 (4%) of 1559 low-risk participants (HR 5·15, 95% CI 3·41-7·76; p<0·0001, after adjustment for basline eGFR and UACR). In the intention-to-treat trial cohort, development of microalbuminuria was seen in 35 (33%) of 107 in the placebo group and 26 (25%) of 102 in the spironolactone group (HR 0·81, 95% CI 0·49-1·34; p=0·41). In the safety analysis (intention-to-treat trial cohort), events of plasma potassium concentrations of more than 5·5 mmol/L were seen in 13 (13%) of 102 participants in the spironolactone group and four (4%) of 107 participants in the placebo group, and gynaecomastia was seen in three (3%) participants in the spironolactone group and none in the placebo group. One patient died in the placebo group due to a cardiac event (considered possibly related to study drug) and one patient died in the spironolactone group due to cancer, deemed unrelated to study drug. INTERPRETATION: In people with type 2 diabetes and normoalbuminuria, a high-risk score from the urinary proteomic classifier CKD273 was associated with an increased risk of progression to microalbuminuria over a median of 2·5 years, independent of clinical characteristics. However, spironolactone did not prevent progression to microalbuminuria in high-risk patients. FUNDING: European Union Seventh Framework Programme.
1st Department Charles University 3rd Faculty of Medicine Prague Czech Republic
Amsterdam Public Health Research Institute VU University Medical Center Amsterdam Netherlands
Bethesda Diabetes Research Center Hoogeveen Netherlands
Department General Practice and Elderly Care Amsterdam Netherlands
Department of Internal Medicine Nephrology Ziekenhuisgroep Twente Hospital Almelo Netherlands
Department of Nephrology Cyril and Methodius University in Skopje Skopje North Macedonia
Department of Nephrology Ghent University Hospital Ghent Belgium
Diabetes Center Institute for Clinical and Experimental Medicine Prague Czech Republic
Diabetes Vascular Research Foundation Hoogeveen Netherlands
Diabetespraxis Leipzig Germany
Diabetologische Schwerpunktpraxis Diabetologen Hessen Marburg Germany
Division of Nephrology and KfH Renal Unit Hospital St Georg Leipzig Germany
Faculty Hospital Královské Vinohrady Prague Czech Republic
German Center for Diabetes Research Neuherberg Germany
Hannover Clinical Trial Center Hannover Medical School Hannover Germany
Institute of Cardiovascular and Medical Sciences University of Glasgow Glasgow UK
Instituto de Investigacion Sanitaria de la Fundacion Jiménez Díaz UAM Madrid Spain
Martin Luther University Halle Wittenberg Germany
Mosaiques Diagnostics Hannover Germany
Steno Diabetes Center Copenhagen Gentofte Denmark
University Clinic of Endocrinology Diabetes and Metabolic Disorders Skopje Macedonia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025111
- 003
- CZ-PrNML
- 005
- 20201222153700.0
- 007
- ta
- 008
- 201125s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S2213-8587(20)30026-7 $2 doi
- 035 __
- $a (PubMed)32135136
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Tofte, Nete $u Steno Diabetes Center Copenhagen, Gentofte, Denmark.
- 245 10
- $a Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial / $c N. Tofte, M. Lindhardt, K. Adamova, SJL. Bakker, J. Beige, JWJ. Beulens, AL. Birkenfeld, G. Currie, C. Delles, I. Dimos, L. Francová, M. Frimodt-Møller, P. Girman, R. Göke, T. Havrdova, HJL. Heerspink, A. Kooy, GD. Laverman, H. Mischak, G. Navis, G. Nijpels, M. Noutsou, A. Ortiz, A. Parvanova, F. Persson, JR. Petrie, PL. Ruggenenti, F. Rutters, I. Rychlík, J. Siwy, G. Spasovski, M. Speeckaert, M. Trillini, P. Zürbig, H. von der Leyen, P. Rossing, PRIORITY investigators,
- 520 9_
- $a BACKGROUND: Microalbuminuria is an early sign of kidney disease in people with diabetes and indicates increased risk of cardiovascular disease. We tested whether a urinary proteomic risk classifier (CKD273) score was associated with development of microalbuminuria and whether progression to microalbuminuria could be prevented with the mineralocorticoid receptor antagonist spironolactone. METHODS: In this multicentre, prospective, observational study with embedded randomised controlled trial (PRIORITY), we recruited people with type 2 diabetes, normal urinary albumin excretion, and preserved renal function from 15 specialist centres in ten European countries. All participants (observational cohort) were tested with the CKD273 classifier and classified as high risk (CKD273 classifier score >0·154) or low risk (≤0·154). Participants who were classified as high risk were entered into a randomised controlled trial and randomly assigned (1:1), by use of an interactive web-response system, to receive spironolactone 25 mg once daily or matched placebo (trial cohort). The primary endpoint was development of confirmed microalbuminuria in all individuals with available data (observational cohort). Secondary endpoints included reduction in incidence of microalbuminuria with spironolactone (trial cohort, intention-to-treat population) and association between CKD273 risk score and measures of impaired renal function based on estimated glomerular filtration rate (eGFR; observational cohort). Adverse events (particularly gynaecomastia and hyperkalaemia) and serious adverse events were recorded for the intention-to-treat population (trial cohort). This study is registered with the EU Clinical Trials Register (EudraCT 20120-004523-4) and ClinicalTrials.gov (NCT02040441) and is completed. FINDINGS: Between March 25, 2014, and Sept 30, 2018, we enrolled and followed-up 1775 participants (observational cohort), 1559 (88%) of 1775 participants had a low-risk urinary proteomic pattern and 216 (12%) had a high-risk pattern, of whom 209 were included in the trial cohort and assigned to spironolactone (n=102) or placebo (n=107). The overall median follow-up time was 2·51 years (IQR 2·0-3·0). Progression to microalbuminuria was seen in 61 (28%) of 216 high-risk participants and 139 (9%) of 1559 low-risk participants (hazard ratio [HR] 2·48, 95% CI 1·80-3·42; p<0·0001, after adjustment for baseline variables of age, sex, HbA1c, systolic blood pressure, retinopathy, urine albumin-to-creatinine ratio [UACR], and eGFR). Development of impaired renal function (eGFR <60 mL/min per 1·73 m2) was seen in 48 (26%) of 184 high-risk participants and 119 (8%) of 1423 low-risk participants (HR 3·50; 95% CI 2·50-4·90, after adjustment for baseline variables). A 30% decrease in eGFR from baseline (post-hoc endpoint) was seen in 42 (19%) of 216 high-risk participants and 62 (4%) of 1559 low-risk participants (HR 5·15, 95% CI 3·41-7·76; p<0·0001, after adjustment for basline eGFR and UACR). In the intention-to-treat trial cohort, development of microalbuminuria was seen in 35 (33%) of 107 in the placebo group and 26 (25%) of 102 in the spironolactone group (HR 0·81, 95% CI 0·49-1·34; p=0·41). In the safety analysis (intention-to-treat trial cohort), events of plasma potassium concentrations of more than 5·5 mmol/L were seen in 13 (13%) of 102 participants in the spironolactone group and four (4%) of 107 participants in the placebo group, and gynaecomastia was seen in three (3%) participants in the spironolactone group and none in the placebo group. One patient died in the placebo group due to a cardiac event (considered possibly related to study drug) and one patient died in the spironolactone group due to cancer, deemed unrelated to study drug. INTERPRETATION: In people with type 2 diabetes and normoalbuminuria, a high-risk score from the urinary proteomic classifier CKD273 was associated with an increased risk of progression to microalbuminuria over a median of 2·5 years, independent of clinical characteristics. However, spironolactone did not prevent progression to microalbuminuria in high-risk patients. FUNDING: European Union Seventh Framework Programme.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a albuminurie $7 D000419
- 650 _2
- $a diabetes mellitus 2. typu $x farmakoterapie $x patofyziologie $x moč $7 D003924
- 650 _2
- $a diabetické nefropatie $x farmakoterapie $x patofyziologie $x moč $7 D003928
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a časná diagnóza $7 D042241
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a hodnoty glomerulární filtrace $7 D005919
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a antagonisté mineralokortikoidních receptorů $x terapeutické užití $7 D000451
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a proteomika $7 D040901
- 650 _2
- $a spironolakton $x terapeutické užití $7 D013148
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Lindhardt, Morten $u Steno Diabetes Center Copenhagen, Gentofte, Denmark.
- 700 1_
- $a Adamova, Katarina $u University Clinic of Endocrinology, Diabetes and Metabolic Disorders, Skopje, Macedonia.
- 700 1_
- $a Bakker, Stephan J L $u Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
- 700 1_
- $a Beige, Joachim $u Division of Nephrology and KfH Renal Unit, Hospital St Georg, Leipzig, Germany; Martin-Luther University Halle, Wittenberg, Germany.
- 700 1_
- $a Beulens, Joline W J $u Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, Netherlands; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands.
- 700 1_
- $a Birkenfeld, Andreas L $u Department of Internal Medicine IV, Division of Endocrinology, Diabetology, and Nephrology, University Hospital Tübingen, Tübingen, Germany; Institute for Diabetes Research and Metabolic Diseases, Helmholtz Center Munich at Eberhard Karls University of Tübingen, Tübingen, Germany; German Center for Diabetes Research, Neuherberg, Germany.
- 700 1_
- $a Currie, Gemma $u Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
- 700 1_
- $a Delles, Christian $u Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
- 700 1_
- $a Dimos, Ingo $u Diabetespraxis, Leipzig, Germany.
- 700 1_
- $a Francová, Lidmila $u 1st Department, Charles University, Third Faculty of Medicine, Prague, Czech Republic.
- 700 1_
- $a Frimodt-Møller, Marie $u Steno Diabetes Center Copenhagen, Gentofte, Denmark.
- 700 1_
- $a Girman, Peter $u Diabetes Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Göke, Rüdiger $u Diabetologische Schwerpunktpraxis, Diabetologen Hessen, Marburg, Germany.
- 700 1_
- $a Havrdova, Tereza $u Diabetes Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Heerspink, Hiddo J L $u Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
- 700 1_
- $a Kooy, Adriaan $u Bethesda Diabetes Research Center, Hoogeveen, Netherlands; Diabetes Vascular Research Foundation (DVRF), Hoogeveen, Netherlands; University Medical Center Groningen, Groningen, Netherlands.
- 700 1_
- $a Laverman, Gozewijn D $u Department of Internal Medicine/Nephrology, Ziekenhuisgroep Twente Hospital, Almelo, Netherlands.
- 700 1_
- $a Mischak, Harald $u Mosaiques Diagnostics, Hannover, Germany.
- 700 1_
- $a Navis, Gerjan $u Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
- 700 1_
- $a Nijpels, Giel $u Department General Practice and Elderly Care, Amsterdam, Netherlands.
- 700 1_
- $a Noutsou, Marina $u Diabetes Center, 2nd Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Hippokratio General Hospital, Athens, Greece.
- 700 1_
- $a Ortiz, Alberto $u Instituto de Investigacion Sanitaria de la Fundacion Jiménez Díaz UAM, Madrid, Spain.
- 700 1_
- $a Parvanova, Aneliya $u Department of Renal Medicine, Clinical Research Centre for Rare Diseases "Aldo e CeleDaccò": Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Bergamo, Italy.
- 700 1_
- $a Persson, Frederik $u Steno Diabetes Center Copenhagen, Gentofte, Denmark.
- 700 1_
- $a Petrie, John R $u Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
- 700 1_
- $a Ruggenenti, Piero L $u Department of Renal Medicine, Clinical Research Centre for Rare Diseases "Aldo e CeleDaccò": Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Bergamo, Italy.
- 700 1_
- $a Rutters, Femke $u Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, Netherlands.
- 700 1_
- $a Rychlík, Ivan $u 1st Department, Charles University, Third Faculty of Medicine, Prague, Czech Republic; Faculty Hospital Královské Vinohrady, Prague, Czech Republic.
- 700 1_
- $a Siwy, Justyna $u Mosaiques Diagnostics, Hannover, Germany.
- 700 1_
- $a Spasovski, Goce $u Department of Nephrology, Cyril and Methodius University in Skopje, Skopje, North Macedonia.
- 700 1_
- $a Speeckaert, Marijn $u Department of Nephrology, Ghent University Hospital, Ghent, Belgium.
- 700 1_
- $a Trillini, Matias $u Department of Renal Medicine, Clinical Research Centre for Rare Diseases "Aldo e CeleDaccò": Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Bergamo, Italy.
- 700 1_
- $a Zürbig, Petra $u Mosaiques Diagnostics, Hannover, Germany.
- 700 1_
- $a von der Leyen, Heiko $u Hannover Clinical Trial Center, Hannover Medical School, Hannover, Germany.
- 700 1_
- $a Rossing, Peter $u Steno Diabetes Center Copenhagen, Gentofte, Denmark; University of Copenhagen, Copenhagen, Denmark. Electronic address: peter.rossing@regionh.dk.
- 710 2_
- $a PRIORITY investigators
- 773 0_
- $w MED00186388 $t The lancet. Diabetes & endocrinology $x 2213-8595 $g Roč. 8, č. 4 (2020), s. 301-312
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32135136 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222153656 $b ABA008
- 999 __
- $a ok $b bmc $g 1599256 $s 1115797
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 8 $c 4 $d 301-312 $e 20200302 $i 2213-8595 $m The lancet. Diabetes & endocrinology $n Lancet Diabetes Endocrinol $x MED00186388
- LZP __
- $a Pubmed-20201125
